ACSL4 and colorectal cancer: Inhibiting ACSL4 methylation mediated by coactivator-associated arginine methyltransferase 1 enhances ferroptosis in colorectal cancer[113], where prohibiting cyclin-dependent kinase 1 also alleviates resistance to oxaliplatin by modulating ACSL4-mediated ferroptosis[114].